New hope for rare blood cancers: first human trial of PRT12396 begins
Disease control
Recruiting now
This early-stage study tests a new drug, PRT12396, in about 100 people with polycythemia vera or myelofibrosis—rare blood cancers. The main goals are to find a safe dose and check for side effects. Researchers will also look for signs that the drug controls the disease, but this …
Phase 1 • Sponsor: Prelude Therapeutics Incorporated • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC